You are here: Industry Insights > Market News > NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

October 25, 2021

Tag: NMPA , drug regulatory , products

Favorites

The National Medical Products Administration (NMPA) issued a list of the second group of key projects for China's drug regulatory science action plan based on the summary of the implementation of the first group on June 24.

Departments and related affiliated institutions of the NMPA were urged to speedily formulate implementation plans in accordance with related requirements and to further improve their drug regulatory capacities, so as to speed up the marketization of innovative products and better meet the needs of public health.

Previous:Emergency Physicians: We Must Address Vaccine Hesitancy, Correct Misinformation to End Pandemic

Next:Phlow receives approval to join BARDA CDMO network

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases.

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan | Pharmasources.com

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

PharmaSourcesApril 17, 2024

Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Related News

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

You may like